Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).

Benzinga

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

Benzinga

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Benzinga

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk

At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.

Benzinga

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?

Shares of Scienture Holdings, Inc. (NASDAQ:SCNX) are rising Thursday after the comprehensive pharmaceutical product company announced the start of commercial sales for Arbli.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.

Benzinga

Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.

Benzinga

4 Biotech Stocks Lifting Off As Momentum Builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. Here's a look at four stocks showing notable momentum gains.

Benzinga

Wegovy maker Novo Nordisk’s chair and six other board members step down

Surprise shake-up follows row with majority shareholder, which seeks ‘extensive reconfiguration’

The Guardian - UK

CSL and Optus pay millions to executives despite paying no company tax in Australia

Biotech company argues high pay is required to retain and attract ‘world-class’ talent

The Guardian - AU

Ozempic-maker Novo Nordisk To Shake Up Board

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its anti-obesity treatments.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.

Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times from 10 to 12 months…

Axios

Trump announces plan to lower cost of IVF drugs

The effort would pair two Trump priorities: lowering drug prices and making IVF treatment more affordable.

Benzinga

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market

BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday

U.S. stocks were higher, with the Nasdaq Composite gaining more than 50 points on Thursday.

Benzinga

Praxis Precision Medicines Stock Doubles - Here's Why

Praxis Precision Medicines Inc. (NASDAQ:PRAX) stock skyrocketed on Thursday.

Benzinga

Why Mira Pharmaceuticals Shares Rose 69% After Hours?

Mira Pharmaceuticals Inc. (NASDAQ:MIRA) shares jumped 68.94% to $2.23 in after-hours trading on Wednesday.

Benzinga

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Evening Standard

PPE Medpro fails to meet deadline to repay Government almost £122m after ruling

Mrs Justice Cockerill previously ruled that PPE Medpro had breached a contract for millions of surgical gowns during the coronavirus pandemic.

Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Benzinga

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.

1 … 5 6 7 8

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.